Technical Analysis for DFFN - Diffusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 2.05 3.02% 0.06
DFFN closed up 3.02 percent on Friday, August 16, 2019, on 55 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DFFN trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish 3.02%
Lower Bollinger Band Walk Weakness 3.02%

Older signals for DFFN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.
Medicine Biotechnology Cancer Oncology Chemotherapy Cancer Treatments Radiation Radiation Therapy Glioblastoma Macular Degeneration Brain Tumor Signal Transduction Glioblastoma Multiforme Acne Vulgaris Mtor Oncology Applications
Is DFFN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.0
52 Week Low 1.83
Average Volume 102,665
200-Day Moving Average 3.3212
50-Day Moving Average 2.5025
20-Day Moving Average 2.1773
10-Day Moving Average 2.1015
Average True Range 0.1647
ADX 22.98
+DI 13.499
-DI 23.9582
Chandelier Exit (Long, 3 ATRs ) 2.2259
Chandelier Exit (Short, 3 ATRs ) 2.4241
Upper Bollinger Band 2.3614
Lower Bollinger Band 1.9932
Percent B (%b) 0.15
BandWidth 16.910853
MACD Line -0.1353
MACD Signal Line -0.1431
MACD Histogram 0.0078
Fundamentals Value
Market Cap 28.74 Million
Num Shares 14 Million
EPS -2.61
Price-to-Earnings (P/E) Ratio -0.79
Price-to-Sales 0.00
Price-to-Book 15.05
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.26
Resistance 3 (R3) 2.24 2.16 2.22
Resistance 2 (R2) 2.16 2.10 2.16 2.21
Resistance 1 (R1) 2.10 2.07 2.13 2.12 2.20
Pivot Point 2.02 2.02 2.03 2.02 2.02
Support 1 (S1) 1.96 1.96 1.99 1.98 1.90
Support 2 (S2) 1.88 1.93 1.89 1.89
Support 3 (S3) 1.82 1.88 1.88
Support 4 (S4) 1.84